Evidence map›Paper›PMID 42684552›Full record

ArticleMolecular biomedicine2026

A late-stage multi-dimensional intervention rescues lethal viral pneumonia in an aged hamster model.

Ming Zhou, Xuan Liu, Jinxin Miao, Yanzhen Lin, Haiqing Xiao, Kun Wu, Longmei Zhang, Xinglin Li, Xinyi Yang, Lin Chen and 9 more

Abstract read
In one paragraph

Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Ming Zhou *State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Xuan Liu *Clinical Center for Biotherapy, Clinical Research Center for Precision Medicine of Abdominal Tumor of Fujian Province, Xiamen Key Laboratory of Biotherapy, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, China.
Jinxin Miao *Academy of Chinese Medicine Science, Henan University of Chinese Medicine, Zhengzhou, China.
Yanzhen Lin *Department of Obstetrics and Gynecology, Zhongshan Hospital of Xiamen University, Xiamen, China.
Haiqing Xiao *State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Kun WuState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Longmei ZhangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Xinglin LiState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Xinyi YangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Lin ChenState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Jian MaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Wei WangState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China.
Nan XuDepartment of Infectious Diseases, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Jiang LiDepartment of Infectious Diseases, First Affiliated Hospital of Anhui Medical University, Hefei, China.
Huachen ZhuState Key Laboratory of Emerging Infectious Diseases, School of Public Health, Li Ka Shing, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Yi GuanState Key Laboratory of Emerging Infectious Diseases, School of Public Health, Li Ka Shing, Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
Ningshao XiaState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China. nsxia@xmu.edu.cn.
Tong ChengState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China. tcheng@xmu.edu.cn.
Lunzhi YuanState Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences & School of Public Health, National Institute of Diagnostics and Vaccine Development in Infectious Diseases, Xiamen University, Xiamen, China. yuanlunzhi@xmu.edu.cn.ORCID http://orcid.org/0000-0001-7480-0287

Funding

Fundamental Research Funds for the Central Universities 20720220006Fundamental Research Funds for the Central Universities 20720250177National Natural Science Foundation of China 32201152
6 · The paper itself

Abstract

Severe pneumonia caused by respiratory virus infection is one of the main threats to the lifespan of the aged population and physiological aging fundamentally drives poor disease outcomes in respiratory viral infections, necessitating investigation of the underlying mechanisms and the development of effective countermeasures. Pulmonary transcriptomic profiling reveals that diffuse cell death, inadequate antiviral responses, myeloid-driven excessive inflammation and immune-thrombosis dictate the pulmonary microenvironment are typical molecular pathology characteristics of the SARS-CoV-2-infected aged hamsters rather than the adult controls. The elevated pathological baseline and dysregulated immune responses are demonstrated as the key host factors of lethal viral pneumonia in the aged hamsters. Meanwhile, SARS-CoV-2 infection in the adult hamsters usually resulted in an aged-like pulmonary transcriptomic signature, suggesting a potential link among aging, dysregulated immune responses and severe illness. To reverse the progression of lethal severe pneumonia in the aged hamsters, we initiated a multidimensional combination therapy of dexamethasone, heparin and the broad-spectrum viral decoy CoVR-MV at three days after infection. Although single- and dual-drug therapies were insufficient to achieve functional cure, the three-drug combination therapy resulted in a potent reduction of high mortality, body weight loss, viral load, lung pathology and cytokine storm through the synergism of immunoregulatory, anticoagulant and antiviral effects, effectively intercepting the multifaceted pathogenic network. This study highlights physiological aging as a core driver of critical COVID-19 pathogenesis and provides valuable clues for the rational design of multi-drug and multi-target therapies against respiratory viral infections and lethal severe pneumonia in the elderly population.

Indexed as

AgingAnimalsAntiviral AgentsCOVID-19CricetinaeDexamethasoneDisease Models, AnimalDrug Therapy, CombinationHeparinLungMaleMesocricetusSARS-CoV-2Viral LoadAntiviral AgentsDexamethasoneHeparinAgingCombined therapyDisease enhancementFatal severe pneumoniaRespiratory virus infectionsSARS-CoV-2

Identifiers

PMID42684552
PMCPMC13538324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.